tetano
Editor, Senior Moderator
Open Forum Infect Dis
. 2022 Apr 12;9(7)
fac186.
doi: 10.1093/ofid/ofac186. eCollection 2022 Jul.
Effectiveness of Casirivimab-Imdevimab Monoclonal Antibody Treatment Among High-Risk Patients With Severe Acute Respiratory Syndrome Coronavirus 2 B.1.617.2 (Delta Variant) Infection
Mohanad M Al-Obaidi[SUP] 1 [/SUP], Ahmet B Gungor[SUP] 2 [/SUP], Saman Nematollahi[SUP] 1 [/SUP], Tirdad T Zangeneh[SUP] 1 [/SUP], Edward J Bedrick[SUP] 3 [/SUP], Katherine M Johnson[SUP] 4 [/SUP], Nicole E Low-Adegbija[SUP] 5 [/SUP], Ruhaniyah Alam[SUP] 4 [/SUP], Pooja Rangan[SUP] 6 [/SUP], C William Heise[SUP] 7 [/SUP], Venkatesh K Ariyamuthu[SUP] 8 [/SUP], Aneesha Shetty[SUP] 8 [/SUP], Abd Assalam Qannus[SUP] 8 [/SUP], Sangeetha Murugapandian[SUP] 8 [/SUP], Mehmet M S Ayvaci[SUP] 9 [/SUP], Prince Mohan Anand[SUP] 10 [/SUP], Bekir Tanriover[SUP] 8 [/SUP]
Affiliations
Abstract
Background: Real-world data on the effectiveness of neutralizing casirivimab-imdevimab monoclonal antibody (Cas-Imd mAb) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among high-risk patients may inform the response to future SARS-CoV-2 variants.
Methods: This study covers an observational retrospective data analysis in Banner Health Care System sites, mainly in Arizona. During the study period, the prevalence of SARS-CoV-2 Delta variant was between 95% and 100%. Of 29 635 patients who tested positive for coronavirus disease 2019 (COVID-19) between 1 August 2021 and 30 October 2021, in the Banner Health Care System, the study cohort was split into 4213 adult patients who received Cas-Imd mAb (1200 mg) treatment compared to a PS-matched 4213 untreated patients. The primary outcomes were the incidence of all-cause hospitalization, intensive care unit (ICU) admission, and mortality within 30 days of Cas-Imd mAb administration or Delta variant infection.
Results: Compared to the PS-matched untreated cohort, the Cas-Imd mAb cohort had significantly lower all-cause hospitalization (4.2% vs 17.6%; difference in percentages, -13.4 [95% confidence interval {CI}, -14.7 to -12.0]; P < .001), ICU admission (0.3% vs 2.8%; difference, -2.4 [95% CI, -3.0 to -1.9]; P < .001), and mortality (0.2% vs 2.0%; difference, -1.8 [95% CI, -2.3 to -1.3]; P < .001) within 30 days. The Cas-Imd mAb treatment was associated with lower rate of hospitalization (hazard ratio
, 0.22 [95% CI, .19-.26]; P < .001) and mortality (HR, 0.11 [95% CI, .06-.21]; P < .001).
Conclusions: Cas-Imd mAb treatment was associated with a lower hospitalization rate, ICU admission, and mortality within 30 days among patients infected with the SARS-CoV-2 Delta variant.
Keywords: Delta variant; SARS-CoV-2; all-cause hospitalization; casirivimab-imdevimab monoclonal antibody; mortality; propensity matching.
. 2022 Apr 12;9(7)
fac186.doi: 10.1093/ofid/ofac186. eCollection 2022 Jul.
Effectiveness of Casirivimab-Imdevimab Monoclonal Antibody Treatment Among High-Risk Patients With Severe Acute Respiratory Syndrome Coronavirus 2 B.1.617.2 (Delta Variant) Infection
Mohanad M Al-Obaidi[SUP] 1 [/SUP], Ahmet B Gungor[SUP] 2 [/SUP], Saman Nematollahi[SUP] 1 [/SUP], Tirdad T Zangeneh[SUP] 1 [/SUP], Edward J Bedrick[SUP] 3 [/SUP], Katherine M Johnson[SUP] 4 [/SUP], Nicole E Low-Adegbija[SUP] 5 [/SUP], Ruhaniyah Alam[SUP] 4 [/SUP], Pooja Rangan[SUP] 6 [/SUP], C William Heise[SUP] 7 [/SUP], Venkatesh K Ariyamuthu[SUP] 8 [/SUP], Aneesha Shetty[SUP] 8 [/SUP], Abd Assalam Qannus[SUP] 8 [/SUP], Sangeetha Murugapandian[SUP] 8 [/SUP], Mehmet M S Ayvaci[SUP] 9 [/SUP], Prince Mohan Anand[SUP] 10 [/SUP], Bekir Tanriover[SUP] 8 [/SUP]
Affiliations
- PMID: 35791354
- PMCID: PMC9047202
- DOI: 10.1093/ofid/ofac186
Abstract
Background: Real-world data on the effectiveness of neutralizing casirivimab-imdevimab monoclonal antibody (Cas-Imd mAb) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among high-risk patients may inform the response to future SARS-CoV-2 variants.
Methods: This study covers an observational retrospective data analysis in Banner Health Care System sites, mainly in Arizona. During the study period, the prevalence of SARS-CoV-2 Delta variant was between 95% and 100%. Of 29 635 patients who tested positive for coronavirus disease 2019 (COVID-19) between 1 August 2021 and 30 October 2021, in the Banner Health Care System, the study cohort was split into 4213 adult patients who received Cas-Imd mAb (1200 mg) treatment compared to a PS-matched 4213 untreated patients. The primary outcomes were the incidence of all-cause hospitalization, intensive care unit (ICU) admission, and mortality within 30 days of Cas-Imd mAb administration or Delta variant infection.
Results: Compared to the PS-matched untreated cohort, the Cas-Imd mAb cohort had significantly lower all-cause hospitalization (4.2% vs 17.6%; difference in percentages, -13.4 [95% confidence interval {CI}, -14.7 to -12.0]; P < .001), ICU admission (0.3% vs 2.8%; difference, -2.4 [95% CI, -3.0 to -1.9]; P < .001), and mortality (0.2% vs 2.0%; difference, -1.8 [95% CI, -2.3 to -1.3]; P < .001) within 30 days. The Cas-Imd mAb treatment was associated with lower rate of hospitalization (hazard ratio
, 0.22 [95% CI, .19-.26]; P < .001) and mortality (HR, 0.11 [95% CI, .06-.21]; P < .001).
Conclusions: Cas-Imd mAb treatment was associated with a lower hospitalization rate, ICU admission, and mortality within 30 days among patients infected with the SARS-CoV-2 Delta variant.
Keywords: Delta variant; SARS-CoV-2; all-cause hospitalization; casirivimab-imdevimab monoclonal antibody; mortality; propensity matching.